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Background
To asses the efficacy of live attenuated Measles, Mumps,
Rubella (MMR) vaccination in Juvenile Idiopathic Arhtri-
tis (JIA) patients.
Methods
MMR seroprevalence and IgG-levels were retrospectively
determined in 418 JIA patients aged 1–22 years of whom
a stored sample was available. Clinical data and vaccina-
tion status were recorded. Sera were tested by ELISA. MMR
serology of JIA patients was compared to 1989 age-
matched healthy controls (HC), in which serology had
been previously determined. Analyses were adjusted for
age and number of vaccinations.
Results
In the group with no vaccinations, MMR seroprevalence
was significantly lower in JIA patients (measles 63% vs.
92%, mumps 39% vs. 92%, rubella 65% vs. 95%). This
was probably due to higher natural infection rates in HC,
since the majority of HC without vaccination were born in
the period before introduction of MMR vaccination. These
differences diminished after vaccination, although the
overall seroprevalence of mumps and rubella remained
lower in JIA (p < 0.001). MMR seroprevalence and IgG lev-
els were significantly lower in systemic JIA patients. 95
patients using methotrexate had MMR serology compara-
ble to patients without methotrexate.
Conclusion
Differences in MMR seroprevalence between JIA patients
and healthy controls disappear after increasing vaccina-
tions, indicating that JIA patients are able to generate a
serological response to MMR vaccination comparable to
healthy controls. MMR serology is lowest in systemic JIA
patients. Methotrexate does not influence MMR serology.
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